Evekeo ODT

AMPHETAMINES · AMPHETAMINE SULFATE · ORALLY DISINTEGRATING TABLET (DISCONTINUED)

BRAND NO GENERIC DISCONTINUED
STIMULANT · SCHEDULE II · REVIEWED NOV 2026
Reviewed by Tariq Halim, MD — ABPN Board-Certified General Psychiatrist · Editorial policy
Last medical review: November 12, 2026
Tariq Halim, MD reports no conflicts of interest. Contact

Key facts

Drug class
CNS Stimulant · Amphetamines
Active ingredient
amphetamine sulfate
Approved ages (last label)
6–17 years
Form and strengths
Orally disintegrating tablet; Strengths (former): 5, 10, 15, 20 mg (2.5 mg also listed as discontinued)
Usual dose and maximum (label)
Last label: start 5 mg once or twice daily; only rarely above 40 mg/day (product discontinued).
Duration
Short-acting; the label gives no duration (an extra dose 4 to 6 hours later if needed).
DEA schedule
Schedule II controlled substance (CII)
Generic
No generic (see Generic manufacturers)
Label date
Prescribing Information revised 10/2023 (Drugs@FDA)

Label last checked: Oct 2026 — Prescribing Information revised 10/2023 (Drugs@FDA) · Last medical review: November 12, 2026

Educational information only, not medical advice. Do not start, stop or change a medication without your prescriber. Medical disclaimer

Evekeo ODT was an orally disintegrating tablet of racemic amphetamine sulfate (5, 10, 15, 20 mg) for ADHD in children 6–17. The FDA Orange Book lists all strengths as discontinued, and FDA has determined the 2.5 mg strength was not withdrawn for safety or effectiveness reasons. Its last label (10/2023) reported a median peak about 3.5 hours after the tablet dissolved on the tongue. Evekeo tablets remain available.

What it is

Evekeo ODT was a short-acting amphetamine tablet that melted on the tongue. It is no longer made; talk to your clinician about alternatives such as Evekeo tablets or other amphetamine products.

Amphetamine sulfate ODT (racemic), NDA 209905 (Azurity; earlier Arbor). Orange Book: all strengths DISCN; the 2.5 mg strength carries a Federal Register determination that it was not discontinued for safety or effectiveness reasons. Last label (209905s004, revised 10/2023): ADHD in pediatric patients 6–17. From the Evekeo ODT label (20 mg crossover vs Evekeo tablets): exposures comparable; median Tmax ~3.0 h for tablets swallowed with water and ~3.5 h for the ODT without water; mean t½ 10.0 h (d) and ~11.7 h (l) in adults. Food (high-fat meal) delayed the ODT median Tmax from 2.5 to 4.5 h without changing exposure. Schedule II.

When considering this for a patient

Evekeo ODT is no longer available. Patients previously on it can be considered for Evekeo tablets (the label allowed mg-for-mg switching between Evekeo and Evekeo ODT) or another amphetamine formulation.

For patients who cannot swallow tablets, current amphetamine alternatives include Adzenys XR-ODT (extended-release ODT), ProCentra (short-acting liquid), Dyanavel XR, and Arynta. Products are not interchangeable mg-for-mg except where labeled.

Patient profile and niche

Evekeo ODT previously served the following situations (now discontinued):

  • Children 6–17 who could not swallow tablets and needed short-acting racemic amphetamine.
  • Dosing without water (the tablet disintegrated in saliva).

Evekeo ODT is discontinued; current alternatives are listed above.

When it is active

When it was marketed, Evekeo ODT had timing similar to Evekeo tablets: the median peak was about 3.5 hours after the tablet dissolved without water (about 4.5 hours after a high-fat meal). In the Evekeo tablet classroom study, children usually took their dose twice a day, but on the test days they took only the morning dose; it helped from about 45 minutes through 10 hours after that dose (published study, Childress 2015). That study used Evekeo tablets, not the ODT, so no effect window is drawn here.

The interactive tool below is kept for reference only. The curve is a schematic based on labeling data, not a prediction for any individual.

EVEKEO ODT TIMING (REFERENCE — DISCONTINUED)

Enter the times that match your (or your child’s) typical day. The curve shows relative plasma level over clock time.

Evekeo ODT (discontinued) · Peak about 3.5 hours after dissolving on the tongue · Additional doses 4–6 hours apart if needed · The label gives no single-dose onset or duration
The curve shows relative plasma concentration (not guaranteed clinical effect).
Reference only. This product is no longer marketed.
Relative plasma level schematic (not to clinical scale): median Tmax ~3.5 h (ODT without water, fasted), t½ ~10–11.7 h (Evekeo ODT label 12.3). The supporting classroom study used Evekeo tablets, not the ODT: a twice-daily regimen of 10–40 mg/day (described in the label, Section 14, as divided doses), but on the two classroom test days only the morning dose was given, and SKAMP was better than placebo from 0.75 h through 10 h after it (Childress 2015, PubMed 25692608). Because the ODT itself was not studied this way, no effect window is drawn. Individual curves vary.

How it works

Schematic of amphetamine mechanism: DAT and NET reversal with increased dopamine and norepinephrine release
Schematic: amphetamine reduces reuptake through DAT and NET and promotes release of dopamine and norepinephrine (transporter reversal). The VMAT2 (vesicular) step shown reflects general pharmacology literature rather than FDA labeling.

Amphetamine increases dopamine and norepinephrine between nerve cells by blocking their reuptake and promoting their release.

DAT Dopamine transporter: reuptake blocked, release increased
More synaptic dopamine
NET Norepinephrine transporter: reuptake blocked, release increased
More synaptic norepinephrine

Per the label (section 12.1–12.2), amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity, and the mode of therapeutic action in ADHD is not known. Amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Evekeo ODT contained d- and l-amphetamine in a 1:1 (racemic) ratio.

Formulations and duration

Orally disintegrating tablet (discontinued).

STRENGTHS (FORMER)5, 10, 15, 20 mg (2.5 mg also listed as discontinued)
APPROVED AGES (LAST LABEL)6–17 years
ADMINISTRATION (LAST LABEL)Morning, with or without food or liquid; push through the foil with dry hands and let it disintegrate on the tongue
AVAILABILITYDiscontinued (Orange Book)

Appearance

Evekeo ODT tablets were white to off-white, round, with the strength on one side and “EVI” on the other (last FDA label):

  • 5 mg — “5” / “EVI”
  • 10 mg — “10” / “EVI”
  • 15 mg — “15” / “EVI”
  • 20 mg — “20” / “EVI”

If you still have tablets, check the expiration date and ask your pharmacist about safe disposal of any unused supply.

Official package photos and pill identifiers:

Generic manufacturers

No generic amphetamine sulfate ODT is listed in the Orange Book.

ProductNotes
Evekeo ODT (NDA 209905)All strengths discontinued (Orange Book, October 2026)
Evekeo tabletsStill marketed; AA-rated generics available

openFDA/Drugs@FDA list NDA 209905 with the last labeling supplement 209905s004 (10/2023).

Common side effects

The most common side effects in the label were decreased appetite and trouble sleeping. In the open-label Evekeo tablet study, stomach ache, irritability, headache, tiredness, and a faster heartbeat were also reported.

EFFECTFREQUENCYNOTES
Decreased appetiteMost common (≥4% and at least twice placebo)Weight and growth are checked
Trouble sleepingMost common (≥4% and at least twice placebo)Take in the morning; avoid late doses
Stomach ache15% (open-label tablet study)Tell your clinician if it persists
Irritability or mood swings14% irritability, 9% affect lability (open-label)Report mood changes
Headache13% (open-label tablet study)Tell your clinician if it persists
Faster heartbeat9% (open-label tablet study)Monitored routinely

The last Evekeo ODT label (Section 6.1) reports the open-label Evekeo tablet study: decreased appetite (28%), infections (22%), abdominal pain (15%), irritability (14%), headache (13%), insomnia (10%), fatigue (10%), affect lability (9%), tachycardia (9%), nausea, vomiting, and dry mouth (6% each). Boxed warning for abuse, misuse, and addiction; assess risk before prescribing and reassess during treatment. Warnings include risks to patients with serious cardiac disease, increased blood pressure and heart rate, psychiatric adverse reactions (screen for bipolar disorder risk), long-term suppression of growth in pediatric patients, peripheral vasculopathy including Raynaud’s phenomenon, seizures, serotonin syndrome with serotonergic drugs, and motor and verbal tics/worsening of Tourette’s syndrome. Contraindicated in patients with known hypersensitivity to amphetamine products or other ingredients (angioedema and anaphylaxis have been reported with other amphetamine products), and with MAOIs, during use or within 14 days of stopping, including linezolid or intravenous methylene blue, because of the risk of hypertensive crisis. Acidifying agents (e.g., ascorbic acid) decrease and alkalinizing agents (e.g., sodium bicarbonate) increase amphetamine blood levels; adjust the dose based on response (label 2 and 7.1).

Dosing considerations

When marketed, children 6–17 started at 5 mg once or twice a day, increasing by 5 mg weekly; doses above 40 mg a day were rarely needed.

Before starting, your clinician should ask about heart problems, including any family history of sudden death or irregular heart rhythm, do a physical exam, and ask about tics or Tourette’s syndrome in you or your family.

Outside the label: large studies of health records in children, young adults and adults have not found a higher rate of heart attack, stroke or sudden cardiac death during ADHD medicine use. The label’s heart warnings and the checks above still apply.

Last label: ages 6–17, start 5 mg once or twice daily; additional dose after 4–6 hours if needed; titrate by 5 mg weekly; only in rare cases exceed 40 mg/day. Evekeo to Evekeo ODT switching was mg-for-mg; other amphetamine products were not to be substituted mg-for-mg.

Pre-treatment screening (last label, 2.1): assess for cardiac disease with a careful history, family history of sudden death or ventricular arrhythmia, and physical exam; assess the family history and clinically evaluate for motor or verbal tics or Tourette’s syndrome.

Baseline ECG: The label’s pre-treatment cardiac assessment (above) is history, family history and examination; it does not call for a routine ECG. NICE NG87 states that an ECG is not needed before starting stimulants unless a feature listed in 1.7.5 is present (e.g., congenital heart disease or previous cardiac surgery, sudden cardiac death in a first-degree relative under 40, exertional breathlessness or syncope, paroxysmal palpitations, cardiac-sounding chest pain, signs of heart failure, a murmur, or adult hypertension) or a co-existing condition is treated with a medicine that adds cardiac risk; those features call for a cardiology opinion (1.7.4–1.7.5). The AAP 2019 guideline asks for a history of cardiac symptoms and a family history of sudden death, WPW, hypertrophic cardiomyopathy and long QT, with further evaluation if any risk factor is present. A Canadian joint position statement (Warren 2009) and the European ADHD Guidelines Group (Graham 2011) do not recommend routine ECG screening; Graham notes that the American Heart Association’s 2008 statement first proposed an ECG as standard and then left it to clinician discretion. In one US screening series, 8.1% of ECGs were abnormal but heart disease was found in 0.3% (Mahle 2009).

Outside the label (class-level cohorts; see Clinical evidence from published studies, Heart and blood pressure): current ADHD-medicine use was not associated with serious cardiovascular events in 1,200,438 people aged 2–24 (aHR 0.75, 95% CI 0.31–1.85; a doubling of risk could not be ruled out; Cooper 2011, PubMed 22043968) or in 150,359 adult users aged 25–64 (current vs remote use RR 1.03, 0.86–1.24; Habel 2011, PubMed 22161946). In FDA Sentinel (2,012,948 initiators of amphetamine products, methylphenidate or atomoxetine), new heart failure/cardiomyopathy was <50 per 10,000 person-years under age 45 (Mosholder 2018, PubMed 30102629).

Planned breaks from medicine (weekends and holidays)

Some families leave out doses on weekends or during school holidays. This is sometimes called a medication holiday or treatment break. Plan any break with the prescriber instead of stopping on your own.

Breaks are usually considered for poor appetite, slow weight gain, trouble sleeping, slowed growth, or to see whether the medicine is still needed. The label says children who are not growing or gaining weight as expected may need to have treatment paused.

In studies, breaks helped appetite, sleep and weight gain. It is less clear that they help a child end up taller: one older study saw a height benefit only after two summers off, and a newer trial found that weekend breaks did not speed up height growth. ADHD symptoms can return on days off, so breaks tend to suit lower-pressure times. If you try one, watch how things go at home and with friends, and restart if problems come back.

Growth warning (Evekeo tablet label, Warnings; the ODT label is no longer posted): monitor height and weight during treatment of pediatric patients; those not growing or gaining height or weight as expected may need treatment interrupted. NICE NG87 lists a planned break among options when weight loss is a concern (1.8.6), suggests considering a break over school holidays to allow catch-up growth when height is significantly affected (1.8.7), and advises periodic trial periods off medication or at a lower dose when the balance of benefit and harm suggests it (1.10.3). The AACAP 2007 practice parameter suggests considering a holiday when height or weight crosses two percentile lines, provided off-medication weekends or summers are not markedly impairing, and regards low-stress periods such as vacations (not the start of a school year) as a good time for a discontinuation trial.

Evidence (see Clinical evidence: Growth, below): in a 4-week RCT of twice-daily IR methylphenidate, weekend placebo reduced insomnia without a significant rise in weekend parent or Monday teacher ratings (Martins 2004, n=40). In children with stimulant-associated weight loss, school-days-only dosing increased weight velocity but not height velocity, and most families in that arm resumed after-school dosing because of symptoms (Waxmonsky 2020). Two summers off methylphenidate were followed by a height benefit; one summer was not (Klein 1988). A review of 22 studies found 25–70% of families use breaks (Ibrahim 2015). In the observational MTA follow-up, consistent long-term use was associated with about 2.4 cm lower adult height (Swanson 2017). Data in adults are sparse.

Pregnancy and breastfeeding

Tell your clinician if you are pregnant, plan to become pregnant, or are breastfeeding. Babies born to mothers taking amphetamines during pregnancy have a higher risk of premature birth and low birth weight. Newborns exposed to amphetamines before birth should be watched for withdrawal symptoms such as feeding problems, irritability, agitation, or unusual sleepiness.

Outside the label: large studies of US and Swedish health records did not find that children exposed to amphetamines before birth were more likely to be diagnosed with autism or ADHD once the parent’s own health was taken into account. Some studies found a small increase in preeclampsia (high blood pressure in pregnancy) and in early (preterm) birth, mostly when a stimulant was continued after the first 3 months. Absolute risks stayed low. Decisions about continuing treatment are best made with your clinician. See Clinical evidence from published studies (Pregnancy) below.

Breastfeeding is not recommended while taking Evekeo ODT, because the medicine passes into breast milk.

A national pregnancy registry collects information about ADHD medicines used during pregnancy. You or your clinician can enroll by calling 1-866-961-2388.

Pregnancy (label 8.1): published epidemiologic studies and postmarketing reports on prescription amphetamine have not identified a drug-associated risk of major birth defects or miscarriage. Premature delivery and low birth weight have been seen in infants of mothers taking amphetamines. Amphetamines cause vasoconstriction that may reduce placental perfusion and can stimulate uterine contractions; monitor exposed infants for withdrawal (feeding difficulties, irritability, agitation, excessive drowsiness). Animal data: dextroamphetamine was embryotoxic in A/Jax and C57BL mice at about 6 times the maximum human dose, but not in New Zealand white rabbits. Registry: National Pregnancy Registry for Psychostimulants (as named in the last label), 1-866-961-2388.

Lactation (label 8.2): limited case reports show amphetamine in human milk (relative infant dose 2% to 13.8% of the maternal weight-adjusted dose; milk/plasma ratio 1.9 to 7.5). No adverse effects in breastfed infants have been reported; long-term neurodevelopmental effects are unknown, and large doses might interfere with milk production, especially when lactation is not well established. The label advises that breastfeeding is not recommended during treatment.

Outside the label (observational cohorts; see Clinical evidence from published studies, Pregnancy): second-half-of-pregnancy amphetamine/dextroamphetamine exposure was not associated with child autism (aHR 0.80, 95% CI 0.56–1.14) or ADHD (aHR 1.07, 0.89–1.28) in US Medicaid (4,693 exposed) and commercial (2,372 exposed) cohorts (Suarez 2024; PubMed 38265792); a Swedish cohort of 861,650 children meta-analysed with Danish data gave a pooled HR for any neurodevelopmental disorder of 1.00 (0.83–1.20) (Bang Madsen 2025; PubMed 40148550). Stimulant use in early pregnancy (amphetamine-dextroamphetamine n=3,331) was associated with preeclampsia (aRR 1.29, 1.11–1.49), and continuation after 20 weeks with preterm birth (aRR 1.30, 1.10–1.55), with small absolute increases (Cohen 2017; PubMed 29112657). In 10,265 matched US patients, continuation into the 2nd/3rd trimester was associated with pre-eclampsia (RR 1.42, 1.19–1.69) and preterm birth (RR 1.34, 1.12–1.62), but first-trimester-only exposure was not (preterm RR 0.75) (Hasan 2026; PubMed 41400021). First-trimester malformation data remain limited (MGH registry, mixed amphetamine salts n=173, lisdexamfetamine n=40: OR 0.39, 0.09–1.61; Szpunar 2023; PubMed 37235505). These findings do not change the label’s section 8.1 statement.

Outside the label: LactMed (NCBI Bookshelf, “Amphetamine,” revised Jun 2025; NBK501307) says some evidence suggests amphetamine at prescribed doses does not harm breastfed infants, but effects on infant neurodevelopment have not been well studied and large doses might reduce milk supply, especially before lactation is well established; it notes that most manufacturers advise against breastfeeding, while some experts consider prescribed doses acceptable if the infant is watched for irritability, poor sleep and feeding problems; breastfeeding is generally discouraged during active amphetamine misuse. This is LactMed’s summary of published data, not FDA label content.

Availability and shortages

DISCONTINUED Evekeo ODT is discontinued. The FDA Orange Book lists all strengths as discontinued, and the product does not appear on current FDA or ASHP shortage lists because it is no longer marketed.

Talk to your clinician about switching to Evekeo tablets or another amphetamine product.

Orange Book (October 2026): NDA 209905, all products DISCN; 2.5 mg with Federal Register determination that it was not discontinued for safety or effectiveness reasons. No DailyMed SPL is currently listed for Evekeo ODT.

How Evekeo ODT compares to other amphetamine products

Evekeo ODT is one of several amphetamine-family options. Effect windows below come from each product’s FDA labeling (clinical study time points or dosing intervals), not head-to-head comparisons; amphetamine products are not interchangeable milligram for milligram.

Medication Studied effect window / dosing (label) Release design Key practical notes
Evekeo ODT (discontinued) Short-acting; once or twice daily Immediate release; orally disintegrating Orange Book: all strengths discontinued (not for safety reasons).
Evekeo (amphetamine sulfate tablet) Short-acting; doses 4–6 h apart (classroom study: 0.75–10 h after a single morning dose) Immediate release; racemic 1:1 d:l Also labeled for narcolepsy and short-term exogenous obesity. AA generics.
Adzenys XR-ODT (disintegrating tablet) Once daily; bioequivalent dose table vs Adderall XR 50% immediate + 50% delayed release; 3:1 d:l Dissolves on tongue; ages 6+. AB-rated generic listed; ASHP lists brand and AG available.
ProCentra (dextroamphetamine solution) Short-acting; first dose on awakening, 1–2 more at 4–6 h intervals Immediate-release liquid, 5 mg/5 mL Bubblegum-flavored liquid; ADHD ages 3–16. AA generic solution listed.
Zenzedi (dextroamphetamine tablet) Short-acting; first dose on awakening, 1–2 more at 4–6 h intervals Immediate release Seven strengths 2.5–30 mg; ADHD ages 3–16. AA generics.
Adderall (mixed salts IR tablet) Short-acting; first dose on awakening, 1–2 more at 4–6 h intervals Immediate release; 3:1 d- to l-amphetamine salts Brand (Teva) and many AB generics; IR tablets on FDA and ASHP shortage lists.

Other amphetamine-family pages: Adderall, Adderall XR, Adzenys XR-ODT, Arynta, Desoxyn, Dexedrine Spansule, Dyanavel XR, Evekeo, Mydayis, ProCentra, Vyvanse, Xelstrym, Zenzedi.

Clinical evidence from published studies

These findings come from published research, not from the FDA label. The FDA label is the official source for approved uses, doses and warnings. Results from studies may not apply to you. Uses marked off-label are not FDA-approved. Talk with your prescriber before making any change.

Items summarize peer-reviewed publications, checked against the PubMed abstract (or full text where stated); figures are reproduced only where the source states them. The FDA label governs approved indications and dosing. Off-label items are not FDA-approved uses. Industry funding or sponsor affiliation is noted where the PubMed record shows it; absence of a note does not mean no industry involvement.

Studies of this medicine (1 study)
  • Randomized controlled trial

    Evekeo (amphetamine sulfate tablets)

    In a classroom study of children aged 6–12, Evekeo was usually taken twice a day, but on the test days children took only their morning dose. That single morning dose improved attention and behavior from 45 minutes through 10 hours after dosing, the last time point tested. Reduced appetite was the most common side effect.

    This study used Evekeo tablets (racemic amphetamine sulfate), not the orally disintegrating version.

    107 enrolled; 8-week open-label twice-daily titration (second dose 4–6 h after the first; final daily doses 10–40 mg), then 97 randomised to crossover (R-AMPH→placebo n=47; placebo→R-AMPH n=50). On the 2 laboratory classroom days only the morning dose was given. SKAMP/PERMP at 0.75, 2, 4, 6, 8, 10 h: SKAMP-Combined significant at every time point (p<0.0001), onset 45 min through 10 h. Open-label TEAEs: decreased appetite 27.6%, upper abdominal pain 14.3%, irritability 14.3%, headache 13.3%. Methods details from open-access full text (PMC4491157).

    Funding / affiliation: Funded by Arbor Pharmaceuticals (Evekeo manufacturer), per the full text.

    Childress AC, Brams M, Cutler AJ, et al. (2015). The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study. J Child Adolesc Psychopharmacol 25(5):402-14. DOI · PubMed 25692608

How ADHD medicines compare (10 studies)
  • Network meta-analysis

    ADHD medicines (class)

    A large analysis of 133 short-term trials found that every ADHD medicine studied worked better than placebo on clinician ratings in children and teens. Amphetamines had the largest average effect, and methylphenidate was the only medicine also shown to beat placebo on teacher ratings. Amphetamines and guanfacine led to more stopping for side effects than placebo in children. Weighing benefit and side effects, the authors favored methylphenidate first in children and amphetamines first in adults. There was too little data to judge effects beyond about 12 weeks.

    Network meta-analysis of 133 double-blind RCTs (efficacy near 12 wk: 10,068 children/adolescents; 8,131 adults). Children, clinician-rated SMD vs placebo: amphetamines −1.02 (95% CI −1.19 to −0.85), methylphenidate −0.78 (−0.93 to −0.62), atomoxetine −0.56 (−0.66 to −0.45). Teacher-rated: only methylphenidate (−0.82, −1.16 to −0.48) and modafinil separated from placebo. Adults, clinician-rated: amphetamines −0.79 (−0.99 to −0.58), methylphenidate −0.49 (−0.64 to −0.35), atomoxetine −0.45 (−0.58 to −0.32). Discontinuation for adverse events vs placebo: amphetamines OR 2.30 (1.36–3.89) in children and 3.26 (1.54–6.92) in adults; guanfacine 2.64 (1.20–5.81) in children; atomoxetine 2.33 (1.28–4.25) and methylphenidate 2.39 (1.40–4.08) in adults only. Head-to-head clinician-rated efficacy favored amphetamines over methylphenidate, atomoxetine and modafinil. Insufficient data at 26 and 52 weeks.

    Funding / affiliation: Non-industry (Stichting Eunethydis; UK NIHR Oxford Health BRC).

    Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727-738. DOI · PubMed 30097390

  • Network meta-analysis

    ADHD treatments in children and teens (class)

    Across 190 trials in children and teens, methylphenidate, amphetamine, atomoxetine, guanfacine and clonidine all worked better than placebo. Methylphenidate and amphetamine appeared more effective than atomoxetine and guanfacine. Behavioral therapy combined with a stimulant appeared better than either medicine type alone. Most effective medicines also caused harms such as reduced appetite, weight loss and sleep problems.

    Bayesian network meta-analyses of 190 RCTs (52 interventions, 26,114 participants; ≥3 weeks follow-up). Medications more efficacious than placebo: methylphenidate, amphetamine, atomoxetine, guanfacine, clonidine. Methylphenidate and amphetamine more efficacious than atomoxetine and guanfacine; methylphenidate and clonidine better accepted (all-cause discontinuation) than placebo and atomoxetine. Behavioural therapy plus stimulants appeared superior to stimulants or nonstimulants alone. Harms included anorexia, weight loss and insomnia. Results expressed as ORs with credible intervals (not reproduced here).

    Catalá-López F, Hutton B, Núñez-Beltrán A, et al. (2017). The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One 12(7):e0180355. DOI · PubMed 28700715

  • Network meta-analysis

    ADHD medicines (class): dose

    An analysis of how benefit changes with dose (113 trials) found that, in children and teens, extra benefit stopped rising above about 45 mg/day of methylphenidate, 25 mg/day of amphetamines and 4 mg/day of guanfacine, although data at higher doses were thin. Stopping for side effects rose at higher amphetamine doses, and at methylphenidate doses above 50 mg/day in adults. No dose–benefit pattern was found for atomoxetine in fixed-dose studies.

    Dose-effect NMA (Bayesian restricted cubic splines) of 113 double-blind RCTs: 68 pediatric (14,138 participants), 45 adult (11,016). Children/adolescents: median efficacy increased up to ~45 mg/day methylphenidate, ~25 mg/day amphetamines, ~4 mg/day guanfacine, with no evidence of added benefit above (wide credible intervals). Adults: amphetamines plateaued above ~50 mg/day; methylphenidate showed no plateau (sparse data). Dose-dependent AE-related discontinuation: amphetamines above 25 mg/day (children) and 50 mg/day (adults); methylphenidate above 50 mg/day in adults, no clear dose dependence in children. No dose-effect pattern for atomoxetine (fixed-dose studies) or modafinil. Needs full-text check: how amphetamine products were converted to a common dose scale is not stated in the abstract.

    Funding / affiliation: Non-industry (UK NIHR).

    Nourredine M, Jurek L, Hamza T, et al. (2026). Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis. Lancet Psychiatry 13(6):485-495. DOI · PubMed 42134365

  • Meta-analysis

    Amphetamines vs methylphenidate (class)

    A pooled analysis of 23 placebo-controlled trials in children and teens found that amphetamine products had somewhat larger average effects than methylphenidate products, even after adjusting for differences in study design. The trials did not compare the two directly.

    Meta-analysis/meta-regression of 23 double-blind placebo-controlled trials (11 drugs, 19 outcome measures). Effect sizes for amphetamine products were significantly, though moderately, greater than for methylphenidate products after correcting for design features. Indirect comparison (no head-to-head trials).

    Faraone SV, Buitelaar J (2010). Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19(4):353-64. DOI · PubMed 19763664

  • Network meta-analysis

    Adult ADHD treatments (class)

    In adults (113 trials), stimulants and atomoxetine were the only treatments that reduced core symptoms on both self-ratings and clinician ratings at 12 weeks. Several psychological approaches (such as CBT and mindfulness) helped only on clinician ratings. Atomoxetine and guanfacine were stopped more often than placebo.

    Component NMA, 113 RCTs (14,887 adults). 12-week core symptoms: atomoxetine SMD −0.38 self-rated (−0.56 to −0.21), −0.51 clinician-rated (−0.64 to −0.37); stimulants about −0.39 self-rated (CI −0.52 to −0.26) and −0.61 clinician-rated (−0.71 to −0.51). CBT (−0.76), cognitive remediation, mindfulness, psychoeducation and tDCS beat placebo on clinician-rated measures only. Acceptability worse than placebo: atomoxetine OR 1.43 (1.14–1.80), guanfacine 3.70 (1.22–11.19).

    Ostinelli EG, Schulze M, Zangani C, et al. (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Lancet Psychiatry 12(1):32-43. DOI · PubMed 39701638

  • Meta-analysis

    Amphetamines in adults (Cochrane review)

    A Cochrane review of 19 short trials in 2,521 adults found that amphetamines reduced ADHD symptoms compared with placebo but did not keep more people in treatment, and more people stopped because of side effects. Lisdexamfetamine and mixed amphetamine salts each reduced clinician-rated symptoms; the one small dextroamphetamine trial did not show a clear effect. The reviewers rated the evidence low or very low quality; 16 of the 19 studies were industry funded.

    Cochrane systematic review (searches to Aug 2017): 19 RCTs, N=2,521 adults, mean study length 5.3 weeks. Clinician-rated severity: amphetamines SMD −0.90 (95% CI −1.04 to −0.75; 13 studies, 2,028; low to very low quality). By type: lisdexamfetamine −1.06 (−1.26 to −0.85; 7 studies, 896), MAS −0.80 (−0.93 to −0.66; 5 studies, 1,083), dexamphetamine −0.24 (−0.80 to 0.32; 1 study, 49; very low). Retention RR 1.06 (0.99–1.13); withdrawal for adverse events RR 2.69 (1.63–4.45). No dose–response or IR vs ER difference. 16 industry funded, 1 public, 2 not reported; none at low risk of bias in all domains.

    Funding / affiliation: 16 of the 19 included trials were funded by the pharmaceutical industry (1 publicly funded, 2 not reported).

    Castells X, Blanco-Silvente L, Cunill R (2018). Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 8(8):CD007813. DOI · PubMed 30091808

  • Meta-analysis

    Amphetamines in children and adolescents (Cochrane review)

    A Cochrane review of 23 short-term trials in 2,675 children and teens aged 3 to 17 found that amphetamines reduced ADHD symptoms compared with placebo, as rated by parents, teachers and clinicians, and about three times as many children were rated as responders. Appetite loss, trouble sleeping and stomach pain were more common. The reviewers rated the evidence low to very low quality and found no evidence favoring one amphetamine product over another, or long-acting over short-acting forms.

    Cochrane systematic review (searches to Aug 2015): 23 RCTs (8 parallel, 15 crossover), N=2,675, ages 3–17, all placebo-controlled. Parent-rated SMD −0.57 (95% CI −0.86 to −0.27; very low quality); teacher −0.55 (−0.83 to −0.27; low); clinician −0.84 (−1.32 to −0.36; very low). CGI-I responders RR 3.36 (2.48–4.55; 9 studies, 2,207; very low). Decreased appetite RR 6.31 (2.58–15.46); insomnia RR 3.80 (2.12–6.83); abdominal pain RR 1.44 (1.03–2.00). 11 studies high risk of bias, 12 unclear. No difference between amphetamine preparations or release formulations.

    Punja S, Shamseer L, Hartling L, et al. (2016). Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2(2):CD009996. DOI · PubMed 26844979

  • Meta-analysis

    Stimulant dose and dosing strategy in children and adolescents

    Pooling 65 trials in 7,877 children and teens, higher stimulant doses brought more symptom improvement but also more stopping because of side effects in fixed-dose trials, and the added benefit got smaller above about 20 mg a day of amphetamine (30 mg of methylphenidate). In trials where doses were adjusted to each child, benefit kept rising across the FDA-approved dose range without more dropouts. The authors favor adjusting the dose to response and side effects.

    Dose-response meta-analysis, 65 RCTs, n=7,877 children/adolescents; MPH and AMP analysed separately (doses converted to MPH- or AMP-equivalents); fixed-dose and flexible-dose trials stratified. Fixed-dose: efficacy and AE-related discontinuation both increased with dose; incremental efficacy decreased beyond 30 mg MPH or 20 mg AMP. Flexible-dose: efficacy increased and all-cause discontinuation decreased with dose; incremental benefit constant across the FDA-licensed range. Group-level estimates; long-term effects of high doses not addressed.

    Farhat LC, Flores JM, Behling E, et al. (2022). The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Mol Psychiatry 27(3):1562-1572. DOI · PubMed 35027679

  • Randomized controlled trial

    Trying both dextroamphetamine and methylphenidate (children 9–14)

    In a small crossover trial, 36 children aged 9 to 14 who had never taken ADHD medicine each tried methylphenidate, dextroamphetamine and placebo for 2 weeks apiece. Each stimulant worked well for 26 children (72%), but many children responded differently to the two. Trying both raised the number with a good response from 26 to 33 (92%).

    Randomized, counterbalanced crossover (2 weeks each of methylphenidate, dextroamphetamine and placebo); n=36 medication-naive children aged 9–14. Outcomes: QbTest and parent/teacher ADHD questionnaire. Group effects similar for both stimulants; each produced a favourable response in 26 children; including both increased favourable responders from 26 (72%) to 33 (92%). Shifting from the inferior to the best drug increased overall response strength by 64% (mean). NCT01220440.

    Ramtvedt BE, Røinås E, Aabech HS, et al. (2013). Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials. J Child Adolesc Psychopharmacol 23(9):597-604. DOI · PubMed 23659360

  • Cohort / registry study

    Switching stimulant family in adults starting treatment

    In a clinic study of 49 adults starting their first stimulant, 41% needed to switch to the other stimulant family (methylphenidate to amphetamine or the reverse) within 90 days because of side effects. Switching was more common after starting methylphenidate. Baseline features did not predict who would need to switch.

    Naturalistic clinical cohort; n=49 medication-naive adults aged 18–45 with DSM-5 ADHD; 67% started a methylphenidate product, 33% an amphetamine product. 41% switched stimulant family within 90 days because of poor tolerability; switching rate higher with initial methylphenidate; formulation changes or added anxiety/depression treatment more frequent with amphetamine. Switching not adequately predicted by baseline characteristics. Small, single-site.

    Biederman J, DiSalvo M, Green A, et al. (2021). How Frequent Is Switching From an Initial Stimulant Family to the Alternative One in the Clinical Setting?: A Pilot Study of 49 Consecutively Referred Medication-Naive Adults With Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmacol 41(3):310-314. DOI · PubMed 33657069

Long-term real-world outcomes (8 studies)
  • Cohort / registry study

    Specific ADHD medicines in adolescents and adults (Sweden)

    In 221,714 Swedish adolescents and adults with ADHD followed for about 7 years, periods on amphetamine, lisdexamfetamine, dexamphetamine or methylphenidate were linked to fewer psychiatric hospital stays than periods off medicine in the same people. Lisdexamfetamine, dexamphetamine and methylphenidate periods were also linked to less suicidal behavior. Only atomoxetine was linked to less work disability. Observational: an association, not proof.

    Nationwide register cohort, Sweden 2006–2021, ages 16–65, n=221,714 (methylphenidate users 151,837; lisdexamphetamine 78,106); within-individual stratified Cox models, mean follow-up 7.0 y. Psychiatric hospitalization aHR: amphetamine 0.74 (95% CI 0.61–0.90), lisdexamphetamine 0.80 (0.78–0.82), dexamphetamine 0.88 (0.83–0.94), methylphenidate 0.93 (0.92–0.95); no association for modafinil, atomoxetine, clonidine, guanfacine. Suicidal behaviour aHR: dexamphetamine 0.69 (0.53–0.89), lisdexamphetamine 0.76 (0.68–0.84), methylphenidate 0.92 (0.86–0.98). Work disability: atomoxetine only, 0.89 (0.82–0.97).

    Taipale H, Bergström J, Gèmes K, et al. (2024). Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes. JAMA Netw Open 7(3):e242859. DOI · PubMed 38506810

  • Cohort / registry study

    ADHD medicines (class): criminal convictions

    Comparing the same 25,656 people with ADHD in Sweden during periods on and off medicine (2006–2009), criminal convictions were 32% lower in men and 41% lower in women while they were taking ADHD medicine. This links treatment with fewer crimes but cannot prove the medicine caused the drop.

    This study looked at ADHD medicines as a group; the abstract does not report amphetamine products separately.

    Swedish registers 2006–2009, n=25,656; stratified (within-individual) Cox regression, medicated vs non-medicated periods. Criminality: men adjusted HR 0.68 (95% CI 0.63–0.73); women HR 0.59 (0.50–0.70). Reductions of 17% to 46% in male sensitivity analyses (including by drug type, stimulant vs nonstimulant, and type of crime). Class-level estimate.

    Funding / affiliation: Non-industry (Swedish Research Council and others).

    Lichtenstein P, Halldner L, Zetterqvist J, et al. (2012). Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 367(21):2006-14. DOI · PubMed 23171097

  • Cohort / registry study

    ADHD medicines (class): risk of death

    In a Swedish national study of 148,578 people aged 6 to 64 newly diagnosed with ADHD, those who started ADHD medicine had a lower risk of dying over the next 2 years (39 vs 48 deaths per 10,000 people). The difference came mainly from fewer deaths from unnatural causes such as injuries, accidental poisonings and suicide; deaths from natural causes did not differ significantly. This is an observational study: it shows an association, not proof that the medicine caused the difference.

    This study looked at ADHD medicines as a group; the abstract does not report amphetamine products separately.

    Target trial emulation, Swedish registers (diagnosis 2007–2018; 2-year follow-up); n=148,578, of whom 84,204 (56.7%) started medication within 3 months. 2-year mortality 39.1 vs 48.1 per 10,000 (risk difference −8.9; 95% CI −17.3 to −0.6). All-cause HR 0.79 (0.70–0.88); unnatural-cause HR 0.75 (0.66–0.86); natural-cause HR 0.86 (0.71–1.05), not significant. Class-level estimate (all ADHD medicines); the abstract does not report methylphenidate separately.

    Li L, Zhu N, Zhang L, et al. (2024). ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA 331(10):850-860. DOI · PubMed 38470385

  • Cohort / registry study

    ADHD medicines (class; 88% started on methylphenidate)

    Using the same Swedish registers (148,581 people aged 6 to 64 newly diagnosed with ADHD), starting ADHD medicine was linked over 2 years to fewer first episodes of suicidal behavior (about 17% fewer), substance misuse (15%), transport accidents (12%) and criminal offenses (13%). Accidental injuries were not significantly reduced for first events, but repeat events of all five kinds were lower. Methylphenidate was the first medicine for 88% of people who started treatment. Observational: an association, not proof.

    This study looked at ADHD medicines as a group; the abstract does not report amphetamine products separately.

    Target trial emulation, Swedish registers 2007–2020; n=148,581; 84,282 (56.7%) initiated treatment, methylphenidate in 74,515 (88.4%). First events, adjusted IRR: suicidal behaviour 0.83 (95% CI 0.78–0.88); substance misuse 0.85 (0.83–0.87); transport accidents 0.88 (0.82–0.94); criminality 0.87 (0.83–0.90); accidental injuries 0.98 (0.96–1.01), not significant. Recurrent events: all five reduced (IRR 0.75–0.96). Class-level estimates.

    Zhang L, Zhu N, Sjölander A, et al. (2025). ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ 390:e083658. DOI · PubMed 40803836

  • Self-controlled case series

    ADHD medicines (class): changes over time

    A Swedish study of 247,420 people who used ADHD medicine between 2006 and 2020 compared periods on and off medicine in the same people. Medicine periods were consistently linked to fewer self-harm events, unintentional injuries, traffic crashes and crimes. However, the links for injuries, crashes and crime became weaker over time as the share of people taking ADHD medicine rose from 0.6% to 2.8%.

    This study looked at ADHD medicines as a group; the abstract does not report amphetamine products separately.

    Self-controlled case series, Swedish registers, ages 4–64, n=247,420; periods 2006–2010, 2011–2015 and 2016–2020 (medication prevalence 0.6% to 2.8%). Medicated vs non-medicated IRR ranges: self-harm 0.77 (0.73–0.81) to 0.85 (0.82–0.88); unintentional injury 0.87 (0.84–0.89) to 0.93 (0.91–0.95); traffic crashes 0.71 (0.67–0.77) to 0.87 (0.83–0.91); crime 0.73 (0.71–0.75) to 0.84 (0.82–0.85). Weakening over time for injury, crashes and crime (P for trend <.01), not fully explained by changes in age and sex mix.

    Li L, Coghill D, Sjölander A, et al. (2025). Increased Prescribing of Attention-Deficit/Hyperactivity Disorder Medication and Real-World Outcomes Over Time. JAMA Psychiatry 82(8):830-837. DOI · PubMed 40560574

  • Cohort / registry study

    ADHD medicines (class): motor vehicle crashes (US)

    In US insurance claims for about 2.3 million people with ADHD, emergency visits for car crashes were 38% lower in men and 42% lower in women during months when they were taking ADHD medicine than in months when they were not. Observational: an association, not proof that the medicine caused the difference.

    This study looked at ADHD medicines as a group; the abstract does not report amphetamine products separately.

    US commercial claims 2005–2014, n=2,319,450 (mean age 32.5; 51.7% female); within-individual comparison of medicated vs unmedicated months. ED visits for MVCs: men OR 0.62 (95% CI 0.56–0.67), women OR 0.58 (0.53–0.62); similar across age groups and sensitivity analyses. Population-attributable fraction up to 22.1% (modelled). Class-level estimate.

    Chang Z, Quinn PD, Hur K, et al. (2017). Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes. JAMA Psychiatry 74(6):597-603. DOI · PubMed 28492937

  • Cohort / registry study

    ADHD medicines (class): substance-related emergencies (US)

    In US insurance claims for almost 3 million teens and adults with ADHD, emergency visits related to substance use were about a third lower during months on ADHD medicine than months off it, and somewhat lower 2 years later in men. This does not support the worry that treatment raises later substance problems, though it cannot prove cause.

    This study looked at ADHD medicines as a group; the abstract does not report amphetamine products separately.

    US commercial claims 2005–2014, n=2,993,887 adolescents and adults (47.2% female); within-individual analyses of stimulant or atomoxetine treatment months. Concurrent substance-related ED visits: men OR 0.65 (95% CI 0.64–0.67), women 0.69 (0.67–0.71). Two years after medication periods: men 0.81 (0.78–0.85), women 0.86 (0.82–0.91); long-term results less consistent in women. Class-level estimate.

    Quinn PD, Chang Z, Hur K, et al. (2017). ADHD Medication and Substance-Related Problems. Am J Psychiatry 174(9):877-885. DOI · PubMed 28659039

  • Cohort / registry study

    ADHD medicines (class): suicidal behavior (Sweden)

    In 37,936 Swedish patients with ADHD followed from 2006 to 2009, comparing the same people on and off treatment, periods on stimulant medicine were linked to fewer suicide attempts and suicides. At the population level, treated people had more events, which reflects who gets treated rather than an effect of the medicine.

    This study looked at ADHD medicines as a group; the abstract does not report amphetamine products separately.

    Swedish registers, n=37,936, 2006–2009; 7,019 suicide-related events in 150,721 person-years. Population-level HR 1.31 (95% CI 1.19–1.44); within-patient HR 0.89 (0.79–1.00); stimulant users within-patient 0.81 (0.70–0.94); non-stimulant/mixed 0.96 (0.72–1.30). Class-level estimate.

    Chen Q, Sjölander A, Runeson B, et al. (2014). Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 348:g3769. DOI · PubMed 24942388

Heart and blood pressure (9 studies)
  • Meta-analysis

    Methylphenidate, amphetamines, atomoxetine (children)

    Pooling 18 trials in 5,837 children and teens, methylphenidate, amphetamines and atomoxetine all raised systolic blood pressure slightly on average. Amphetamines and atomoxetine also raised heart rate and diastolic pressure; methylphenidate did not. About 2% stopped because of heart-related effects. The authors advise regular heart rate and blood pressure checks.

    Systematic review/meta-analysis, 18 trials (10 MPH, 5 AMP, 7 ATX), n=5,837, mean 28.7 weeks. Pre–post SBP SMD: MPH 0.25 (0.08–0.42), AMP 0.09 (0.03–0.15), ATX 0.16 (0.04–0.27). DBP: AMP 0.16 (0.03–0.29), ATX 0.22 (0.10–0.34); HR: AMP 0.37 (0.13–0.60), ATX 0.43 (0.26–0.60); MPH no pre–post effect on DBP or HR. No significant head-to-head differences. 2% discontinued for any cardiovascular effect.

    Hennissen L, Bakker MJ, Banaschewski T, et al. (2017). Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs 31(3):199-215. DOI · PubMed 28236285

  • Network meta-analysis

    ADHD medicines (class)

    Pooling 102 short-term trials, most ADHD medicines raised blood pressure and pulse modestly, and stimulants did not raise them more than atomoxetine or viloxazine. Guanfacine lowered blood pressure and pulse. The authors advise monitoring blood pressure and pulse with any ADHD medicine, not just stimulants.

    NMA of 102 RCTs (13,315 children/adolescents; 9,387 adults; median 7 weeks). Children, mean increase vs placebo: SBP 1.07 (atomoxetine) to 1.81 mm Hg (methylphenidate); DBP 1.93 (amphetamines) to 2.42 (methylphenidate); pulse 2.79 bpm (viloxazine) to 5.58 bpm (atomoxetine). Amphetamines, lisdexamfetamine and methylphenidate not associated with larger increments than atomoxetine or viloxazine. Guanfacine in children: SBP −2.83 (−3.8 to −1.85), DBP −2.08, pulse −4.06. Only four RCTs informed medium-term effects. CINeMA confidence mostly low to moderate in children, very low in adults.

    Funding / affiliation: Non-industry (UK NIHR).

    Farhat LC, Lannes A, Del Giovane C, et al. (2025). Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 12(5):355-365. DOI · PubMed 40203844

  • Case-control study

    ADHD medicines (class), long-term use

    In a Swedish registry study of 278,027 people with ADHD (ages 6–64), longer total use of ADHD medicine was linked to a higher risk of cardiovascular disease, about 4% more per year of use, mainly high blood pressure and arterial disease. This kind of study shows an association, not proof of cause.

    Nested case-control (Swedish registers, 2007–2020): 10,388 CVD cases vs 51,672 matched controls. Cumulative use vs non-use: 3–≤5 y AOR 1.27 (1.17–1.39); >5 y 1.23 (1.12–1.36). Per year of use AOR 1.04 (1.03–1.05), steeper in first 3 years (1.08). Hypertension 3–≤5 y AOR 1.72 (1.51–1.97), >5 y 1.80 (1.55–2.08). Similar in under-25s and adults. Not broken down by individual drug in the abstract.

    Zhang L, Li L, Andell P, et al. (2024). Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry 81(2):178-187. DOI · PubMed 37991787

  • Clinical practice guideline

    Stimulants and nonstimulants (children and teens)

    The 2019 American Academy of Pediatrics guideline says stimulants have not been shown to raise the risk of sudden death. Before starting, clinicians should ask about heart symptoms and a family history of sudden death or inherited heart rhythm or muscle conditions, and arrange further evaluation if any risk factor is present. It describes an ECG as part of that extra evaluation for nonstimulants when risk factors are present.

    AAP clinical practice guideline (Wolraich 2019), full text: obtain history of specific cardiac symptoms and family history of sudden death, cardiovascular symptoms, WPW, HCM and long QT before stimulants; if risk factors are present, obtain additional evaluation. For nonstimulants with risk factors, the additional evaluation is described as an ECG, with pediatric cardiology referral if abnormal. No routine ECG is recommended for patients without risk factors.

    Wolraich ML, Hagan JF Jr, Allan C, et al. (2019). Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics 144(4). DOI · PubMed 31570648

  • Clinical practice guideline

    ADHD medicines (class)

    The European ADHD Guidelines Group found no evidence that a routine ECG before starting ADHD medicine adds benefit. It notes that the American Heart Association first suggested an ECG as standard in 2008 and then left it to the clinician’s judgment. A 2009 Canadian joint statement likewise recommends a careful history and examination, with an ECG or cardiology referral only when these suggest a problem.

    European Guidelines Group (EUNETHYDIS) review of adverse effects, full text: “no current evidence to suggest an incremental benefit for routine ECG assessment” before medication; AHA in 2008 initially recommended ECG as standard, then changed this to clinician discretion; ECG screening not considered cost-effective for preventing sudden death in the general pediatric population. Canadian Paediatric Society / Canadian Cardiovascular Society / CACAP joint statement (Warren 2009, abstract): thorough history and physical examination; no routine ECG screening or cardiac subspecialist consultation unless indicated by history or examination.

    Graham J, Banaschewski T, Buitelaar J, et al. (2011). European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20(1):17-37. DOI · PubMed 21042924

    See also: Warren AE, Hamilton RM, Bélanger SA, et al. (2009). Can J Cardiol. DOI · PubMed 19898693

  • Cohort / registry study

    Children with ADHD (screening ECG)

    At one U.S. center, 1,470 children with ADHD had a screening ECG. About 8% were read as abnormal, but heart disease was found in only 5 children (0.3%), so most abnormal results were false alarms. Finding each true case cost about $17,000 in testing.

    Retrospective review of screening ECGs in 1,470 patients <21 y with ADHD (Apr–Sep 2008): 119 abnormal (8.1%); follow-up included 63 echocardiograms, 5 stress tests, 9 Holters; cardiac disease in 5 (0.3%: ventricular pre-excitation 2, bicuspid aortic valve 2, secundum ASD 1); positive predictive value 4.2%; mean cost $58 per child and $17,162 per true positive. The authors note screening can find asymptomatic disease but with low PPV.

    Mahle WT, Hebson C, Strieper MJ (2009). Electrocardiographic screening in children with attention-deficit hyperactivity disorder. Am J Cardiol 104(9):1296-9. DOI · PubMed 19840580

  • Cohort / registry study

    ADHD medicines (class): new heart failure or cardiomyopathy (FDA Sentinel)

    Among about 2 million people starting amphetamine products (including lisdexamfetamine), methylphenidate or atomoxetine in the FDA Sentinel database, new heart failure or cardiomyopathy was uncommon under age 45 (fewer than 50 cases per 10,000 person-years) and did not rise with longer use. Rates were highest in people 65 and older soon after starting, which may reflect existing heart risk.

    FDA Sentinel distributed database; 2,012,948 initiators of amphetamine products (incl. lisdexamfetamine), methylphenidate or atomoxetine (44.6% female; 54.1% <22 y). Heart failure/cardiomyopathy <50 per 10,000 person-years in ages <22 and 22–44, without trend by duration of use (up to 1,095 days). Highest rate in ≥65 y in days 0–90 (950 per 10,000 person-years). No comparison group.

    Mosholder AD, Taylor L, Mannheim G, et al. (2018). Incidence of Heart Failure and Cardiomyopathy Following Initiation of Medications for Attention-Deficit/Hyperactivity Disorder: A Descriptive Study. J Clin Psychopharmacol 38(5):505-508. DOI · PubMed 30102629

  • Cohort / registry study

    ADHD medicines (class): serious heart events in children and young adults

    In US health-plan records for 1.2 million children and young adults aged 2 to 24, current use of ADHD medicine was not linked to more sudden cardiac death, heart attack or stroke. Such events were rare (3 per 100,000 person-years). The study could not rule out a small increase, but any extra risk in absolute terms would be low.

    This study looked at ADHD medicines as a group; the abstract does not report amphetamine products separately.

    Retrospective cohort, 4 US health plans; 1,200,438 aged 2–24 y, 2,579,104 person-years (373,667 current use). 81 serious cardiovascular events (3.1 per 100,000 person-years). Current users vs nonusers: adjusted HR 0.75 (95% CI 0.31–1.85); current vs former 0.70 (0.29–1.72). Upper CI limit means a doubling could not be ruled out. Class-level (not reported by drug).

    Funding / affiliation: Funded by the Agency for Healthcare Research and Quality and the FDA.

    Cooper WO, Habel LA, Sox CM, et al. (2011). ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365(20):1896-904. DOI · PubMed 22043968

  • Cohort / registry study

    ADHD medicines (class): serious heart events in adults 25–64

    In US health-plan records for 150,359 adults aged 25 to 64 taking methylphenidate, amphetamine or atomoxetine, each matched with two non-users, current or new use was not linked to more heart attacks, sudden cardiac deaths or strokes. The apparent lower risk in users most likely reflects that healthier people were prescribed the medicines.

    This study looked at ADHD medicines as a group; the abstract does not report amphetamine products separately.

    Retrospective cohort, 4 US sites; 150,359 users matched 1:2 to nonusers (443,198 total); 806,182 person-years (median 1.3 y). Current use vs nonuse adjusted RR 0.83 (95% CI 0.72–0.96); new users 0.77 (0.63–0.94); current vs remote use 1.03 (0.86–1.24); new vs remote 1.02 (0.82–1.28). Apparent protective associations attributed to healthy-user bias. Class-level.

    Habel LA, Cooper WO, Sox CM, et al. (2011). ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 306(24):2673-83. DOI · PubMed 22161946

Growth (5 studies)
  • Randomized controlled trial

    Stimulants (mostly OROS methylphenidate), children 5–12

    Children whose weight dropped after starting a stimulant were randomly assigned to medicine on school days only (a planned break on weekends and holidays), a daily high-calorie snack, or monthly checks. All three helped weight gain, but none of them sped up growth in height. Most families in the school-days-only group went back to giving the medicine after school because symptoms got worse.

    RCT, 230 children aged 5–12 starting stimulants (78%, mainly OROS-MPH) or behavioral treatment for 30 months; children with a BMI decline >0.5 z after 6 months (n=71) were randomized to monthly monitoring, drug holidays (medication limited to school days) or a 150-kcal daily supplement. Weight velocity rose after randomization across all arms (β=0.271, SE 0.027, p<.001); per actual use, supplementation (p<.01) and holidays (p<.05) increased weight velocity more than monitoring. No arm increased height velocity. Full text: parents gave medication on only 5% of weekend days in the holiday arm; 16 of 23 (70%) reverted to after-school dosing because of worsening symptoms.

    Waxmonsky JG, Pelham WE 3rd, Campa A, et al. (2020). A Randomized Controlled Trial of Interventions for Growth Suppression in Children With Attention-Deficit/Hyperactivity Disorder Treated With Central Nervous System Stimulants. J Am Acad Child Adolesc Psychiatry 59(12):1330-1341. DOI · PubMed 31473291

  • Randomized controlled trial

    Methylphenidate (immediate-release, twice daily)

    In a 4-week trial in boys taking methylphenidate twice a day, swapping in a placebo on weekends led to less trouble sleeping and a trend toward better appetite. ADHD symptoms on weekends (parent ratings) and on the following Monday (teacher ratings) did not rise significantly. The study was small and short.

    Double-blind RCT, 28 days, boys with ADHD: MPH b.i.d. 7 days/week (n=21) vs weekdays with weekend placebo (n=19). No significant group difference in parent weekend ratings (endpoint p=0.41, ES 0.26) or Monday teacher ratings (p=0.99, ES 0.002). Weekend placebo: less insomnia (F=3.96, p=0.05) and a trend to less appetite interference (F=3.18, p=0.08). Growth was not an outcome.

    Martins S, Tramontina S, Polanczyk G, et al. (2004). Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol 14(2):195-206. DOI · PubMed 15319017

  • Randomized controlled trial

    Methylphenidate (long-term use)

    Children on long-term methylphenidate were randomly assigned to stop or continue it over two summers. One summer off was followed by more weight gain but no height difference; two summers off had a significant positive effect on height. The study could not show whether this changes final adult height.

    Controlled withdrawal study: hyperactive children on long-term MPH randomized to be off or remain on medication over two consecutive summers. After one summer: no height difference, higher weight in the off-medication group. After two summers: significant positive effect on height (not weight). Authors note the results do not address long-term effects on height. Needs full-text check: sample size and effect sizes are not in the abstract.

    Klein RG, Landa B, Mattes JA, et al. (1988). Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry 45(12):1127-30. DOI · PubMed 3058088

  • Systematic review (narrative)

    ADHD medicines (mostly stimulants), children and teens

    A review of 22 studies from 1972 to 2013 found that 25–70% of families take breaks from ADHD medicine, most often during school holidays. Breaks are used to check whether medicine is still needed and to manage side effects. Longer breaks were linked to better growth, and shorter breaks could reduce sleep problems and improve appetite.

    Literature review (22 studies, 1972–2013) of drug holidays in children and adolescents. Prevalence 25–70% of families, more often in school holidays; purposes: testing ongoing need, managing adverse effects and tolerance. Positive impact on growth with longer breaks; shorter breaks could reduce insomnia and improve appetite. Study quality not graded in the abstract.

    Ibrahim K, Donyai P (2015). Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades. J Atten Disord 19(7):551-68. DOI · PubMed 25253684

  • Cohort / registry study

    Stimulants (MTA follow-up into adulthood)

    In the long-term follow-up of the MTA study, young adults who had taken stimulants consistently through childhood were on average about 2.4 cm shorter than those who took them inconsistently, and treated groups were about 2.6 cm shorter than those who took little or none. Consistent long-term use was not linked to fewer adult ADHD symptoms. These groups were not randomized.

    Observational follow-up of the MTA (579 randomized; 515 followed; 289 classmates as local norms), outcomes at ~25 years. Adult height: Consistent/Inconsistent users 2.55 ± 0.73 cm shorter than Negligible users (p<.0005); Consistent 2.36 ± 1.13 cm shorter than Inconsistent (p<.04). Naturalistic-subgroup comparisons for symptom severity were not significant. Full text: height was measured in 402 ADHD participants (Consistent subgroup n=33).

    Swanson JM, Arnold LE, Molina BSG, et al. (2017). Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry 58(6):663-678. DOI · PubMed 28295312

Psychosis and mania (3 studies)
  • Cohort / registry study

    Amphetamine vs methylphenidate

    In US insurance data on 221,846 adolescents and young adults (13–25) starting a stimulant, new psychosis treated with an antipsychotic occurred in about 1 in 660. It was about twice as common with amphetamine (0.21%) as with methylphenidate (0.10%).

    Propensity-matched cohort (2 claims databases, 2004–2015): 110,923 MPH vs 110,923 amphetamine starters. 343 psychosis episodes: 106 (0.10%) MPH vs 237 (0.21%) amphetamine; HR 1.65 (95% CI 1.31–2.09) for amphetamine.

    Funding / affiliation: Non-industry (NIMH and others).

    Moran LV, Ongur D, Hsu J, et al. (2019). Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. N Engl J Med 380(12):1128-1138. DOI · PubMed 30893533

  • Case-control study

    Amphetamines (class)

    Among young people hospitalized for psychiatric reasons, recent prescription amphetamine use was linked to higher odds of a first episode of psychosis or mania, and the link was strongest at higher doses (above 30 mg of dextroamphetamine-equivalent). Recent methylphenidate use was not linked. Because only hospitalized patients were compared, results may not apply to everyone.

    Case-control (McLean Hospital EHR, 2005–2019): 1,374 cases (incident psychosis/mania, ages 16–35) vs 2,748 psychiatric controls. Past-month amphetamine aOR 2.68 (1.90–3.77); >30 mg dextroamphetamine equivalents ~5.28-fold. Methylphenidate aOR 0.91 (0.54–1.55). Selection bias acknowledged.

    Moran LV, Skinner JP, Shinn AK, et al. (2024). Risk of Incident Psychosis and Mania With Prescription Amphetamines. Am J Psychiatry 181(10):901-909. DOI · PubMed 39262211

  • Meta-analysis

    Stimulants in ADHD (class): psychosis and bipolar disorder

    Pooling 16 studies of about 391,000 people with ADHD, a 2025 review estimated that roughly 2% to 4% of people treated with stimulants later had psychotic symptoms, a psychotic disorder or bipolar disorder, although results varied widely between studies. Psychosis was more common with amphetamines than with methylphenidate. These studies cannot show that the medicine caused the problems, and the authors advise discussing these risks and watching for them during treatment.

    Systematic review and meta-analysis (searches to Oct 1, 2024), 16 studies, N=391,043 (mean age 12.6 y). Pooled occurrence among stimulant-treated individuals: psychotic symptoms 2.76% (95% CI 0.73–9.88; k=10), psychotic disorder 2.29% (1.52–3.40; k=4), bipolar disorder 3.72% (0.77–16.05; k=4); heterogeneity I² >95%. Psychosis, amphetamines vs methylphenidate: OR 1.57 (1.15–2.16; k=3, n=231,325). Higher occurrence in North American studies, with longer follow-up, more female participants, smaller samples and higher stimulant doses. Observational data; causality not established.

    Salazar de Pablo G, Aymerich C, Chart-Pascual JP, et al. (2025). Occurrence of Psychosis and Bipolar Disorder in Individuals With Attention-Deficit/Hyperactivity Disorder Treated With Stimulants: A Systematic Review and Meta-Analysis. JAMA Psychiatry 82(11):1103-1112. DOI · PubMed 40900605

Other safety findings (1 study)
  • Meta-analysis

    Stimulants and tics (children)

    Pooling 22 placebo-controlled trials in 2,385 children with ADHD, new or worse tics were reported about as often on stimulants (5.7%) as on placebo (6.5%). Type of stimulant, dose and treatment length made no difference. The authors suggest that tics appearing during treatment are often coincidental and that retrying the stimulant may be reasonable.

    This study looked at ADHD medicines as a group; the abstract does not report amphetamine products separately.

    Meta-analysis of 22 double-blind, randomized, placebo-controlled trials; n=2,385 children with ADHD. Tic event rate 5.7% (95% CI 3.7–8.6%) on psychostimulants vs 6.5% (4.4–9.5%) on placebo; RR 0.99 (0.78–1.27; p = .962). No effect of stimulant type, dose, duration, recorder or age; crossover designs showed higher measured risk than parallel-group trials.

    Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. (2015). Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials. J Am Acad Child Adolesc Psychiatry 54(9):728-36. DOI · PubMed 26299294

ADHD with other conditions (4 studies)
  • Meta-analysis

    ADHD with tic disorders

    In children with ADHD and tics (9 trials), methylphenidate, alpha-2 agonists (clonidine, guanfacine) and atomoxetine improved ADHD symptoms. Alpha-2 agonists and atomoxetine also reduced tics, and methylphenidate did not worsen tics in the short term. Very high doses of dextroamphetamine were linked to worse tics.

    Meta-analysis, 9 studies, 477 subjects. ADHD efficacy: MPH, α2 agonists, desipramine, ATX. Tic improvement: α2 agonists and ATX. No evidence MPH worsened tics short-term; supratherapeutic dextroamphetamine worsened tics. Authors: MPH gave the greatest and most immediate ADHD improvement.

    Bloch MH, Panza KE, Landeros-Weisenberger A, et al. (2009). Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 48(9):884-893. DOI · PubMed 19625978

  • Network meta-analysis

    ADHD with tic disorder or Tourette syndrome (children)

    A network meta-analysis of 8 trials in 575 children and teens with both ADHD and a tic disorder found that stimulants improved ADHD symptoms and did not make tics worse. Alpha-2 agonists (guanfacine or clonidine), alone or with a stimulant, improved both ADHD and tics. The evidence was rated low to very low certainty.

    Network meta-analysis of double-blind RCTs (searches to Sep 2023): 8 RCTs, n=575 with TD + ADHD. Stimulants vs placebo: ADHD SMD −0.54 (95% CI −1.05 to −0.03); tics −0.22 (−0.49 to 0.05), not worsened. α2 agonists: ADHD −0.72 (−1.13 to −0.31), tics −0.70 (−0.96 to −0.45). Stimulants + α2 agonists: ADHD −0.84 (−1.54 to −0.13), tics −0.60 (−1.04 to −0.17). Low to very low certainty (CINeMA).

    Farhat LC, Behling E, Landeros-Weisenberger A, et al. (2024). Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis. J Child Adolesc Psychopharmacol 34(9):373-382. DOI · PubMed 39320340

  • Systematic review (narrative)

    ADHD medicines in bipolar disorder (ISBD task force review)

    A systematic review by an international bipolar disorder task force (17 studies, 2,136 people with bipolar disorder) found that methylphenidate or mixed amphetamine salts may improve ADHD symptoms, with limited evidence on thinking skills. When used together with mood stabilizers, the medicines were not linked to more mania or hypomania.

    ISBD Targeting Cognition Task Force systematic review (searches to Jun 2023): 17 studies, N=2,136 (armodafinil k=4, methylphenidate k=4, bupropion k=4, clonidine k=1, lisdexamphetamine k=1 n=25, mixed amphetamine salts k=1 n=30, modafinil k=2). Three studies found ADHD-symptom reduction (two methylphenidate, one amphetamine salts). No increased (hypo)mania risk observed alongside mood stabilizers. Risk of bias low in 5, moderate in 11, serious in 1.

    Miskowiak KW, Obel ZK, Guglielmo R, et al. (2024). Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force. Bipolar Disord 26(3):216-239. DOI · PubMed 38433530

  • Cohort / registry study

    ADHD medicines (class) in people with epilepsy or a seizure history

    In 21,557 Swedish people with a history of seizures, periods on ADHD medicine were linked to fewer emergency seizure visits than periods off medicine in the same people, and starting medicine was not followed by more seizures. The authors conclude that epilepsy should not automatically rule out ADHD medicine. Observational and class-level.

    This study looked at ADHD medicines as a group; the abstract does not report amphetamine products separately.

    Swedish registers, n=21,557 with a seizure history (born 1987–2003), incl. 6,773 youth with epilepsy; 2006–2013. Among 995 initiators, no significant change in seizure rate in the 24 weeks before vs after initiation. Medication periods vs non-medication periods (within-individual): HR 0.73 (95% CI 0.57–0.94); similar in youth with epilepsy and continuous antiepileptic treatment. Not reported by drug.

    Brikell I, Chen Q, Kuja-Halkola R, et al. (2019). Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy. Epilepsia 60(2):284-293. DOI · PubMed 30682219

Pregnancy (9 studies)

These research findings do not replace the FDA label. For what the label says, see Pregnancy and breastfeeding above.

  • Cohort / registry study

    Methylphenidate and amphetamines

    In very large US and Nordic pregnancy registries, first-trimester methylphenidate was linked to a small increase in heart defects (about 28% higher relative risk), while amphetamines were not linked to more birth defects. Absolute risks remained low.

    Cohort: 1,813,894 US Medicaid pregnancies; Nordic replication 2,560,069. US adjusted RR, MPH: any malformation 1.11 (0.91–1.35), cardiac 1.28 (0.94–1.74); amphetamines: any 1.05 (0.93–1.19), cardiac 0.96 (0.78–1.19). Pooled US+Nordic MPH cardiac RR 1.28 (1.00–1.64). US cardiac risk per 1,000: 12.7 unexposed, 18.8 MPH, 15.4 amphetamines.

    Huybrechts KF, Bröms G, Christensen LB, et al. (2018). Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. JAMA Psychiatry 75(2):167-175. DOI · PubMed 29238795

  • Meta-analysis

    Stimulants and atomoxetine in pregnancy

    A 2026 review of 25 studies found that, after accounting for differences between mothers, using stimulants or atomoxetine in pregnancy was not linked to more major birth defects or to most pregnancy and child-development problems. A small link with methylphenidate and heart defects, and with a low newborn Apgar score, could not be ruled out and needs more study.

    Systematic review/meta-analysis (25 studies; 23 pooled). Major malformations: unadjusted RR 1.25 (1.14–1.37), adjusted 1.04 (0.97–1.12). Cardiovascular malformations aRR 1.20 (0.88–1.63); methylphenidate-specific aRR 1.33 (1.01–1.74). No adjusted association with miscarriage, preterm birth, low birth weight, SGA, NICU admission or offspring neurodevelopmental disorders. Low 5-min Apgar aRR 1.21 (1.03–1.42). Authors attribute crude associations largely to confounding.

    Komargodski R, Tillawe A, Berlin M, et al. (2026). Pregnancy and Offspring Outcomes After Prenatal Stimulant or Atomoxetine Exposure: A Systematic Review and Meta-analysis. Am J Obstet Gynecol MFM 102165. DOI · PubMed 42887725

  • Meta-analysis

    ADHD medicines in pregnancy (class)

    Pooling 8 cohort studies, ADHD medicine during pregnancy was linked to more newborn intensive-care admissions but not to other maternal or newborn problems; methylphenidate showed a borderline link with heart defects.

    Meta-analysis of 8 cohorts. NICU admission RR 1.88 (1.7–2.08) vs never exposed; 1.38 (1.23–1.54) vs exposure before/after pregnancy only. MPH and cardiac malformation RR 1.27 (0.99–1.63; p=0.065). No association with other outcomes; limited confounder adjustment.

    Jiang HY, Zhang X, Jiang CM, et al. (2019). Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 28(3):288-295. DOI · PubMed 30585374

  • Cohort / registry study

    Amphetamine/dextroamphetamine in the second half of pregnancy: child neurodevelopment

    In US Medicaid and private insurance records for more than 4 million pregnancies, children whose mothers took amphetamine/dextroamphetamine in the second half of pregnancy were not more likely to be diagnosed with autism, ADHD or other developmental disorders once other factors, including the mother’s own conditions, were taken into account. Unadjusted numbers were 2 to 3 times higher, which shows how much those other factors matter.

    US cohorts: Medicaid 2000–2018 (2,496,771 unexposed; 4,693 amphetamine/dextroamphetamine-exposed; 786 methylphenidate) and MarketScan 2003–2020 (1,773,501; 2,372; 337). Exposure: dispensing in the second half of pregnancy. Adjusted HRs for amphetamine/dextroamphetamine: autism 0.80 (95% CI 0.56–1.14), ADHD 1.07 (0.89–1.28), any neurodevelopmental disorder 0.91 (0.81–1.28). Methylphenidate: ADHD 1.43 (1.12–1.82), not robust to stricter control for maternal ADHD. Published in JAMA Psychiatry 2024.

    Suarez EA, Bateman BT, Hernandez-Diaz S, et al. (2024). Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. JAMA Psychiatry 81(5):477-488. DOI · PubMed 38265792

  • Cohort / registry study

    ADHD medicines in pregnancy (incl. amphetamines): child neurodevelopment

    A Swedish study of 861,650 children, combined with an earlier Danish study, found no higher risk of autism, ADHD or other developmental disorders in children exposed before birth to methylphenidate, amphetamines or atomoxetine, compared with children whose mothers stopped their medicine before pregnancy. Results were similar when siblings were compared.

    Swedish population cohort 2008–2017: 861,650 children of 572,731 mothers; comparator = maternal discontinuation before conception. Adjusted HR: any NDD 0.95 (95% CI 0.82–1.11), ADHD 0.92 (0.78–1.08), ASD 0.86 (0.63–1.18); consistent by medication type, timing, duration and in sibling comparisons. Meta-analysis with a Danish study: pooled HR any NDD 1.00 (0.83–1.20).

    Bang Madsen K, Larsson H, Skoglund C, et al. (2025). In utero exposure to methylphenidate, amphetamines and atomoxetine and offspring neurodevelopmental disorders - a population-based cohort study and meta-analysis. Mol Psychiatry 30(9):3885-3894. DOI · PubMed 40148550

  • Cohort / registry study

    Stimulants in pregnancy (mostly amphetamine-dextroamphetamine): placental complications

    In US Medicaid records, stimulant use in early pregnancy (mostly amphetamine-dextroamphetamine) was linked to a small rise in preeclampsia, a pregnancy blood-pressure problem (about 29% higher in relative terms; the baseline risk was about 3.7 in 100 pregnancies). Continuing a stimulant after 20 weeks was linked to a small rise in preterm birth. The authors say the absolute increases are small and should not by themselves lead women with significant ADHD to stop treatment.

    US Medicaid 2000–2010: amphetamine-dextroamphetamine (n=3,331), methylphenidate (1,515) and atomoxetine (453, negative control) monotherapy in the first half of pregnancy vs 1,461,493 unexposed. Baseline risks: preeclampsia 3.7%, abruption 1.4%, SGA 2.9%, preterm birth 11.2%. Stimulant aRR: preeclampsia 1.29 (95% CI 1.11–1.49), abruption 1.13 (0.88–1.44), SGA 0.91 (0.77–1.07), preterm 1.06 (0.97–1.16). Continuation after 20 weeks (n=1,319) vs discontinuation (3,527): preterm birth 1.30 (1.10–1.55), preeclampsia 1.26 (0.94–1.67). Atomoxetine not associated.

    Cohen JM, Hernández-Díaz S, Bateman BT, et al. (2017). Placental Complications Associated With Psychostimulant Use in Pregnancy. Obstet Gynecol 130(6):1192-1201. DOI · PubMed 29112657

  • Cohort / registry study

    Stimulants in pregnancy: first trimester only vs continued

    In US commercial insurance records (10,265 matched patients), stimulant use only in the first 3 months of pregnancy was not linked to more complications. Continuing into the second or third trimester was linked to more preeclampsia, high blood pressure in pregnancy, placental abruption and preterm birth than in unexposed pregnancies. Results were similar for amphetamine and methylphenidate products. Observational.

    US commercial claims 2013–2021; 1:1 propensity-matched, n=10,265. First-trimester-only exposure vs none: live birth RR 1.08 (95% CI 1.06–1.10), spontaneous abortion 0.69 (0.64–0.76), preterm birth 0.75 (0.62–0.90). Continued into 2nd/3rd trimester vs none: placental abruption 1.63 (1.03–2.57), pre-eclampsia 1.42 (1.19–1.69), gestational hypertension 1.37 (1.16–1.61), preterm birth 1.34 (1.12–1.62); stillbirth 1.42 (0.76–2.67), not significant. Directionally consistent for amphetamine- and methylphenidate-containing products. J Atten Disord 2026 (epub Dec 2025).

    Hasan SA, Murugappan M, Westberg S, et al. (2026). Prescription Stimulant Continuation in Pregnancy and Birth Outcomes. J Atten Disord 30(3):315-328. DOI · PubMed 41400021

  • Cohort / registry study

    Stimulants in the first trimester: major malformations (US registry)

    In the Massachusetts General Hospital pregnancy registry (1,988 women), babies exposed to a prescription stimulant in the first trimester (mostly mixed amphetamine salts or lisdexamfetamine) did not have more major birth defects than unexposed babies. The study was small, so it can only rule out large risks.

    MGH National Pregnancy Registry for Psychiatric Medications; N=1,988 (mixed amphetamine salts 173, lisdexamfetamine 40, methylphenidate 45, dexmethylphenidate 3; controls 1,755). Major malformations reviewed by a blinded dysmorphologist. OR for any first-trimester stimulant 0.39 (95% CI 0.09–1.61). No major malformations among lisdexamfetamine-, methylphenidate- or dexmethylphenidate-exposed infants. Preliminary. NCT01246765.

    Szpunar MJ, Freeman MP, Kobylski LA, et al. (2023). Risk of Major Malformations in Infants After First-Trimester Exposure to Stimulants: Results From the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. J Clin Psychopharmacol 43(4):326-332. DOI · PubMed 37235505

  • Cohort / registry study

    Stimulants in pregnancy: perinatal outcomes (Canada and Australia)

    In about 554,000 pregnancies in Ontario and 139,000 in New South Wales, pregnancies exposed to prescription stimulants had more complications in raw numbers, but most of these links faded after accounting for other differences between the groups. The authors think stimulants are not a major cause of most of these outcomes. Results for preeclampsia were unclear, and they suggest closer monitoring.

    Population cohorts: Ontario 2002–2017 (N=554,272; 1,360 exposed, 0.25%) and NSW 2003–2011 (N=139,229; 146 exposed, 0.10%); amphetamine, methylphenidate, dextroamphetamine or lisdexamfetamine. IPTW: nearly all associations attenuated. Pre-eclampsia weighted OR 2.02 (95% CI 1.42–2.88) Ontario; 1.50 (0.77–2.94) NSW; 1.24 (0.64–2.40) restricted to social-security beneficiaries. Residual confounding likely.

    Camacho X, Zoega H, Gomes T, et al. (2023). The association between psychostimulant use in pregnancy and adverse maternal and neonatal outcomes: results from a distributed analysis in two similar jurisdictions. Int J Epidemiol 52(1):190-202. DOI · PubMed 36135973

Frequently asked questions

Is Evekeo ODT discontinued?

Yes. The FDA Orange Book lists all strengths as discontinued.

Was it discontinued for safety reasons?

FDA determined that the 2.5 mg strength was not discontinued for safety or effectiveness reasons. The Orange Book does not state a reason for discontinuing the other strengths.

What can replace Evekeo ODT?

Evekeo tablets contain the same medicine, and the label allowed switching between them mg-for-mg. Other options for people who cannot swallow tablets include Adzenys XR-ODT and ProCentra.

Is there a generic Evekeo ODT?

No generic amphetamine sulfate ODT is listed.

Who could take Evekeo ODT?

The last label covered children and adolescents 6–17 with ADHD.

How fast did it work?

The peak was about 3.5 hours after the tablet dissolved, and in the Evekeo tablet classroom study, a single morning dose improved symptoms from about 45 minutes.

Is Adzenys XR-ODT the same thing?

No. Adzenys XR-ODT is an extended-release, once-daily 3:1 amphetamine ODT; Evekeo ODT was short-acting racemic amphetamine sulfate.

What should I do with leftover tablets?

Ask your pharmacist about safe disposal or take-back options for controlled substances.

How long did Evekeo ODT last?

The Evekeo ODT label does not give a duration of effect. It is short-acting: given once or twice daily, with an extra dose 4 to 6 hours later if needed (label section 2.2). Evekeo ODT has since been discontinued.

How was Evekeo ODT taken?

The tablet is placed on the tongue and allowed to disintegrate, without chewing or crushing, and can be taken with or without liquid (label sections 2.2 and 2.3).

Could Evekeo ODT be taken with food?

Yes. The label says to take it in the morning with or without food or liquid (label section 2.2). A high-fat meal did not change total absorption or the peak level (label section 12.3).

Did Evekeo ODT cause a crash or rebound as it wore off?

The Evekeo ODT label does not describe a “crash” or rebound effect. It is short-acting, and the label does not give a duration of effect. If ADHD symptoms, irritability or tiredness come back as a dose wears off, tell your prescriber; the timing or dose may need adjusting.

Evekeo ODT vs Evekeo tablets — what’s the difference?

Both contain racemic amphetamine sulfate and are short-acting. Evekeo ODT dissolved on the tongue and was approved for ADHD in ages 6 to 17; Evekeo tablets are swallowed and are also labeled for narcolepsy and short-term weight loss. Evekeo ODT is discontinued, while Evekeo tablets and their generics remain available. See the Evekeo page and the comparison table above.

What should I do if a dose of Evekeo ODT was missed?

The Evekeo ODT label does not give instructions for a missed dose. It is given in the morning (label section 2.2), and trouble sleeping is one of its most common side effects (Medication Guide). The label only says to take it exactly as prescribed (Medication Guide), so do not take extra to make up for a missed dose; ask your prescriber or pharmacist what to do.

What were the most common side effects of Evekeo ODT?

The Medication Guide lists decreased appetite and trouble sleeping as the most common side effects (label section 6). These are not all the possible side effects; call your prescriber for advice about side effects that bother you.

Is an ECG (heart tracing) needed before starting?

Usually not. Before prescribing, the clinician should ask about fainting, chest pain, a racing heartbeat, known heart problems, and any family history of sudden death or heart rhythm problems, and do a physical exam. An ECG or a visit to a heart specialist is used when any of these raise concern. UK, Canadian and European guidance does not call for a routine ECG when there are no such warning signs.

Can my child take breaks from the medicine on weekends or over the summer?

Sometimes, but plan it with the prescriber. Breaks can help with appetite, weight gain and sleep, and the label says children who are not growing or gaining weight as expected may need treatment paused. Breaks have not been shown to reliably make children taller, and ADHD symptoms can come back on days off, so it depends on how much your child struggles without the medicine. A break can also show whether the medicine is still needed.

Can I take Evekeo ODT while pregnant or breastfeeding?

Tell your clinician if you are pregnant or planning a pregnancy. The Evekeo ODT label reports a higher risk of premature birth and low birth weight with amphetamines in pregnancy and advises watching newborns for withdrawal. Breastfeeding is not recommended during treatment. A pregnancy registry for ADHD medicines can be reached at 1-866-961-2388.

Prescribing guidelines

Amphetamine-class stimulants, like methylphenidates, are first-line pharmacologic options for school-age children, adolescents, and adults with ADHD per major guidelines when medication is indicated.

Sources

  • Arbor Pharmaceuticals, LLC. Evekeo ODT (amphetamine sulfate) orally disintegrating tablets, CII. Prescribing Information, revised 10/2023. Drugs@FDA (accessed Oct 2026).
  • U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), data files dated October 2026. FDA.
  • Childress AC, Brams M, Cutler AJ, et al. The efficacy and safety of Evekeo, racemic amphetamine sulfate, for treatment of attention-deficit/hyperactivity disorder symptoms: a multicenter, dose-optimized, double-blind, randomized, placebo-controlled crossover laboratory classroom study. J Child Adolesc Psychopharmacol. 2015;25(5):402–414. DOI · PubMed 25692608 · PMC4491157 (full text). Funded by Arbor Pharmaceuticals.
  • Wolraich ML, Hagan JF Jr, Allan C, et al.; American Academy of Pediatrics Subcommittee on Children and Adolescents with ADHD. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. AAP.
  • Centers for Disease Control and Prevention. Clinical Care of ADHD in Children (summary of the AAP guideline; updated Oct 21, 2026). CDC (accessed 2026).
  • National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management (NG87), 2018, updated 2019; recommendations 1.7.3–1.7.5, 1.7.20–1.7.22, 1.8.6–1.8.7 and 1.10.3. NICE (accessed Oct 2026).
  • Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921. PubMed 17581453.
  • Drugs and Lactation Database (LactMed). Amphetamine. National Institute of Child Health and Human Development; revised Jun 2025. NCBI Bookshelf NBK501307.
EDUCATIONAL INFORMATION ONLY. Not medical advice. Graphs are schematic illustrations based on publicly available labeling and are not to clinical scale. Availability status is reviewed periodically and may change. Medication decisions require individualized assessment by a qualified clinician. Brand logos are trademarked; official use requires permission. Full medical disclaimer · Privacy
Back to top